Brief: InVivo Therapeutics Announces FDA Acceptance Of Preclinical Module In Support Of Co’S Complete HDE Submission
13/07/2021 13:02
July 13 (Reuters) - InVivo Therapeutics Holdings Corp
NVIV.O :
* INVIVO THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF
PRECLINICAL
MODULE IN SUPPORT OF COMPANY’S COMPLETE HDE SUBMISSION
Source text for Eikon: ID:nBwb4xFsma
Further company coverage: NVIV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on InVivo Therapeutics Holdings
See all newsU.S. STOCKS ON THE MOVE-Gold miners, Dorian LPG, Apple
U.S. STOCKS ON THE MOVE-CMS Energy, SunPower, Etsy
InVivo Therapeutics falls on filing for Chapter 11 bankruptcy
Brief: InVivo Therapeutics Holdings Received Notice Of Delisting Or Failure To Satisfy Standard From Nasdaq
U.S. STOCKS ON THE MOVE-Alibaba, Cisco, CRISPR